Mario Gabelli Clovis Oncology, Inc. Transaction History

Gamco Investors, Inc. Et Al

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$1.05 - $2.85 $13,597 - $36,907	-12,950 Reduced 8.18%	145,400 $173,000
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.96 $9,261 - $43,512	-14,700 Reduced 8.49%	158,350 $285,000
Q1 2022 May 13, 2022	BUY	$1.43 - $3.14 $7,150 - $15,700	5,000 Added 2.98%	173,050 $350,000
Q4 2021 Feb 11, 2022	SELL	$2.7 - $4.76 $76,275 - $134,470	-28,250 Reduced 14.39%	168,050 $455,000
Q3 2021 Nov 12, 2021	SELL	$4.06 - $5.8 $36,540 - $52,200	-9,000 Reduced 4.38%	196,300 $875,000
Q2 2021 Aug 13, 2021	BUY	$5.02 - $7.05 $39,407 - $55,342	7,850 Added 3.98%	205,300 $1.19 Million
Q1 2021 May 14, 2021	SELL	$4.81 - $10.34 $591,630 - $1.27 Million	-123,000 Reduced 38.38%	197,450 $1.39 Million
Q4 2020 Feb 05, 2021	BUY	$4.13 - $6.41 $33,659 - $52,241	8,150 Added 2.61%	320,450 $1.54 Million
Q3 2020 Nov 06, 2020	SELL	$4.82 - $7.72 $36,632 - $58,672	-7,600 Reduced 2.38%	312,300 $1.82 Million
Q2 2020 Aug 13, 2020	BUY	$5.69 - $9.69 $47,227 - $80,427	8,300 Added 2.66%	319,900 $2.16 Million
Q1 2020 May 14, 2020	BUY	$3.77 - $11.0 $14,966 - $43,670	3,970 Added 1.29%	311,600 $1.98 Million
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $185,235 - $1.01 Million	-61,745 Reduced 16.72%	307,630 $3.21 Million
Q3 2019 Nov 01, 2019	BUY	$3.93 - $15.35 $667,412 - $2.61 Million	169,825 Added 85.1%	369,375 $1.45 Million
Q2 2019 Aug 02, 2019	BUY	$12.81 - $25.67 $1.86 Million - $3.72 Million	144,850 Added 264.81%	199,550 $2.97 Million
Q1 2019 May 02, 2019	BUY	$17.66 - $30.28 $966,002 - $1.66 Million	54,700 New	54,700 $1.36 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Gamco Investors, Inc. Et Al, based on Form 13F filings with the SEC.

Stay updated on Gamco Investors, Inc. Et Al and Mario Gabelli with notifications on news.